P2Y12–Phosphodiesterase–cAMP signaling axis (P2Y12–PDE–cAMP axis)

The P2Y12–PDE–cAMP axis is a fundamental signaling network that governs platelet reactivity and thrombotic risk by modulating the intracellular concentration of cyclic adenosine monophosphate (cAMP) [1, 3]. This axis integrates signals from the P2Y12 receptor, a Gi-coupled purinergic receptor activated by ADP, and phosphodiesterases (PDEs), primarily PDE3A, which catalyze the breakdown of cAMP [5, 9]. Under physiological conditions, high cAMP levels maintain platelets in a quiescent state by activating protein kinase A (PKA) and phosphorylating vasodilator-stimulated phosphoprotein (VASP) [1, 13]. Activation of P2Y12 suppresses cAMP production, while PDE activity promotes its degradation, both of which facilitate platelet aggregation and thrombus stabilization [5, 6]. This pathway is the primary target for dual antiplatelet therapy (DAPT), where P2Y12 antagonists (e.g., clopidogrel, ticagrelor) are used to prevent cAMP depletion, and PDE inhibitors (e.g., cilostazol) are employed to further elevate cAMP levels [7, 12]. Consequently, this axis is central to the management of acute coronary syndromes, stroke prevention, and peripheral artery disease [10, 11].

Other names

P2Y12-cAMP pathwayP2Y12-Gi-cAMP signalingADP-P2Y12-cAMP axisP2Y12-PDE3-cAMP axis

Drugs targeting this axis work by either inhibiting the P2Y12 receptor to prevent the Gi-mediated suppression of adenylate cyclase or by inhibiting phosphodiesterases (PDEs) to prevent the degradation of cAMP. Both mechanisms result in elevated intracellular cAMP levels, which activate protein kinase A (PKA) and lead to the phosphorylation of VASP, ultimately inhibiting platelet activation and aggregation [1, 5, 9].